Is lemborexant (dual orexin receptor antagonist) superior to benzodiazepines, Z‑drugs, antihistamines, and over‑the‑counter sleep aids as a first‑line treatment for adult insomnia?

Lemborexant vs. Other Sleep Medications: Evidence-Based Comparison

Lemborexant is not definitively superior to benzodiazepines, Z-drugs, or other first-line insomnia treatments based on current guideline evidence, but it offers a potentially safer alternative with comparable efficacy and a more favorable side effect profile, particularly regarding cognitive impairment and dependence risk.

Guideline Framework

The 2017 American Academy of Sleep Medicine (AASM) guidelines provide the most comprehensive framework for pharmacologic insomnia treatment 1. Critically, all pharmacologic agents received only WEAK recommendations, reflecting limited comparative effectiveness data. The guidelines explicitly state that suvorexant (the first dual orexin receptor antagonist) received a weak recommendation for sleep maintenance insomnia, while eszopiclone, zolpidem, zaleplon, triazolam, and temazepam all received weak recommendations for various insomnia subtypes 1.

The guidelines recommend AGAINST using:

• Diphenhydramine (antihistamines) 1
• Over-the-counter melatonin 1
• Trazodone 1

This creates a clear hierarchy: prescription medications (including orexin antagonists, Z-drugs, and benzodiazepines) are preferred over OTC options.

Key Safety Distinction

The 2016 American College of Physicians evidence report highlights a critical safety concern that favors orexin antagonists: observational studies suggest hypnotics (particularly benzodiazepines and Z-drugs) are associated with increased risk for dementia, fractures, and major injury 2. FDA documents noted that most pharmacotherapies carry risks for cognitive and behavioral changes, including driving impairment 2.

Comparative Efficacy Evidence

Network Meta-Analysis Findings

The most robust comparative data comes from a 2021 network meta-analysis 3:

At 4 weeks, lemborexant ranked:

• Highest for objectively measured total sleep time (TST), latency to persistent sleep (LPS), and sleep efficiency (SE)
• Second to suvorexant for wake after sleep onset (WASO)
• Eszopiclone ranked highest for subjective sleep onset latency and Insomnia Severity Index

Critical interpretation: While lemborexant showed statistical superiority on polysomnography measures, eszopiclone performed better on patient-reported outcomes. This suggests no single agent is universally superior—the choice depends on whether objective sleep architecture or subjective sleep quality is prioritized.

Head-to-Head Comparison with Zolpidem

A 2023 study directly compared lemborexant with zolpidem ER 6.25 mg 4:

For insomnia with short sleep duration (I-SSD, <6 hours):

• Both lemborexant doses (5 mg, 10 mg) significantly improved SOL, TST, and WASO vs. placebo
• Zolpidem ER improved TST and WASO but not SOL
• Lemborexant showed more consistent benefits

For insomnia with normal sleep duration (I-NSD, ≥6 hours):

• Neither drug provided consistent subjective and objective benefits
• This suggests both agents work better for more severe insomnia phenotypes

Recent Meta-Analyses (2025)

Two 2025 meta-analyses provide updated efficacy data 5, 6:

Lemborexant vs. placebo:

• Reduced WASO by 20.73 minutes (95% CI: -28.58 to -12.88) 5
• Improved sleep efficiency by 4.84% (95% CI: 2.69 to 7.00) 5
• Reduced sleep onset latency by 10.85 minutes (95% CI: -18.47 to -3.23) 5

Comparative DORA analysis 7:

• All three DORAs (daridorexant, lemborexant, suvorexant) outperformed placebo
• Lemborexant 10 mg showed the largest effect on subjective time to sleep onset (SMD: -0.430)
• Daridorexant 50 mg showed the largest effect on subjective total sleep time (SMD: -0.475)
• No DORA was definitively superior across all outcomes

Safety Profile Comparison

Lemborexant-Specific Safety

Advantages:

• No evidence of physiological tolerance, withdrawal symptoms, or rebound insomnia 7
• Does not adversely affect sleep architecture 7
• Lower risk of cognitive/psychomotor impairment compared to benzodiazepines 8

Disadvantages:

• Higher risk of somnolence compared to placebo (RR: 4.95) 6 and compared to daridorexant 9
• Increased treatment-related adverse events (RR: 1.82) 5
• FDA drug label warns against concomitant use with moderate CYP3A4 inhibitors like fluconazole due to 4.2-fold increase in exposure 10

Switching Study Evidence

A 2023 real-world study examined switching from benzodiazepines/Z-drugs to lemborexant 11:

• Athens Insomnia Scale scores improved significantly over 3 months (mean change: -3.38, P<0.001)
• Total diazepam equivalents reduced from 14.0 mg to 11.3 mg (P<0.001)
• No increase in daytime sleepiness (Epworth Sleepiness Scale unchanged)
• Cognitive function improved (Perceived Deficits Questionnaire-5 improved)

This suggests lemborexant can facilitate benzodiazepine/Z-drug deprescribing while maintaining efficacy.

Clinical Decision Algorithm

First-Line Pharmacologic Choice:

For sleep onset insomnia:

• Lemborexant 5 mg OR eszopiclone 2-3 mg OR zolpidem 10 mg (women: 5 mg)
• Avoid: Benzodiazepines in older adults (fall risk)
• Avoid: Antihistamines (anticholinergic burden, no evidence)

For sleep maintenance insomnia:

• Lemborexant 5-10 mg OR eszopiclone 2-3 mg OR doxepin 3-6 mg
• Avoid: Short-acting agents (zaleplon, triazolam)

For mixed insomnia (onset + maintenance):

• Lemborexant 5-10 mg OR eszopiclone 2-3 mg OR zolpidem 10 mg
• Lemborexant may have slight edge due to consistent effects on both parameters 4

Prioritize Lemborexant When:

1. Patient is ≥65 years old (lower cognitive impairment risk vs. benzodiazepines/Z-drugs) 8
2. History of falls or fractures (observational data suggests lower risk than benzodiazepines) 2
3. Concern for dependence (no tolerance/withdrawal documented) 7
4. Currently on benzodiazepines/Z-drugs and seeking to taper (switching study supports this) 11
5. Insomnia with objective short sleep duration (<6 hours on PSG) 4

Avoid Lemborexant When:

1. Taking moderate/strong CYP3A4 inhibitors (fluconazole, clarithromycin, etc.) 10
2. Daytime somnolence is primary concern (higher somnolence risk than daridorexant) 9
3. Cost is prohibitive (Z-drugs are generic and less expensive)

Dosing Strategy:

Start with lemborexant 5 mg 12:

• Network meta-analysis suggests 5 mg is similarly effective to 10 mg for most outcomes
• Better tolerated than 10 mg (lower discontinuation rates)
• Titrate to 10 mg only if inadequate response after 1-2 weeks

Common Pitfalls

1. Assuming lemborexant is "safer" means it's always first-line: Guidelines give weak recommendations to ALL agents, including lemborexant. Choice should be individualized based on insomnia subtype, patient age, comorbidities, and medication interactions.

2. Ignoring insomnia phenotype: Lemborexant works better for objective short sleep duration insomnia 4. For normal sleep duration insomnia, efficacy is less consistent—consider cognitive behavioral therapy for insomnia (CBT-I) first.

3. Overlooking drug interactions: Lemborexant exposure increases 4.2-fold with CYP3A4 inhibitors 10. Screen medication lists carefully.

4. Expecting dramatic superiority: Effect sizes are modest across all agents. The 2016 ACP review noted "absolute effect sizes were small" even for agents with statistical significance 2.

5. Using antihistamines or OTC melatonin: Guidelines explicitly recommend against these 1. If patients are using them, switch to evidence-based prescription options.

Bottom Line

Lemborexant is not superior to Z-drugs or benzodiazepines in terms of pure efficacy, but offers a more favorable safety profile regarding cognitive impairment, dependence risk, and potential for facilitating deprescribing of problematic hypnotics. The choice between lemborexant, eszopiclone, or zolpidem should be based on:

• Insomnia subtype (onset vs. maintenance vs. mixed)
• Patient age (lemborexant preferred in older adults)
• Fall/fracture risk (lemborexant preferred)
• Current medication regimen (avoid lemborexant with CYP3A4 inhibitors)
• Cost considerations (generic Z-drugs are cheaper)

For most patients ≥55 years with chronic insomnia and no contraindications, lemborexant 5 mg is a reasonable first-line choice that balances efficacy with a superior safety profile compared to older agents 8, 12.